Powder: -20°C for 3 years | In solvent: -80°C for 1 year
YK-3-237 (B-[2-Methoxy-5-[(1E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propen-1-yl]phenyl]boronic acid) reduces acetylation of mtp53 and exhibits anti-proliferative effects toward triple-negative breast cancer (TNBC) cells carrying mtp53.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 34.00 | |
5 mg | In stock | $ 55.00 | |
10 mg | In stock | $ 89.00 | |
25 mg | In stock | $ 189.00 | |
50 mg | In stock | $ 322.00 | |
100 mg | In stock | $ 563.00 | |
200 mg | In stock | $ 727.00 | |
500 mg | In stock | $ 1,130.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 61.00 |
Description | YK-3-237 (B-[2-Methoxy-5-[(1E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propen-1-yl]phenyl]boronic acid) reduces acetylation of mtp53 and exhibits anti-proliferative effects toward triple-negative breast cancer (TNBC) cells carrying mtp53. |
In vitro | YK-3-237 activates SIRT1 enzyme activities in vitro and deacetylation of both mtp53 in a SIRT1-dependent manner. |
Synonyms | B-[2-Methoxy-5-[(1E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propen-1-yl]phenyl]boronic acid |
Molecular Weight | 372.18 |
Formula | C19H21BO7 |
CAS No. | 1215281-19-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMF: 30 mg/ml(80.60 mM)
Ethanol: 10 mg/ml(26.86 mM)
DMSO: 30 mg/ml(80.60 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
YK-3-237 1215281-19-8 Chromatin/Epigenetic DNA Damage/DNA Repair Sirtuin YK3237 inhibit B-[2-Methoxy-5-[(1E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propen-1-yl]phenyl]boronic acid p53 breast cancer triple-negative mtp53 Mutant TNBC Inhibitor deacetylation YK 3 237 inhibitor